JP2006517201A

JP2006517201A - アミド及びエステルマトリックスメタロプロテアーゼ阻害剤

アミド及びエステルマトリックスメタロプロテアーゼ阻害剤 Download PDF

Info

Publication number: JP2006517201A
Authority: JP; Japan
Prior art keywords: alkylenyl; alkyl; compound; mmp; membered
Prior art date: 2003-01-17
Legal status : Pending

Application number

JP2006500277A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006517201A5 (https=

Inventor

ブンカー，エイミー・メイ

ピカード・ジョセフ・アーマンド

Current Assignee

Warner Lambert Co LLC

Original Assignee

Warner Lambert Co LLC

Priority date

2003-01-17

Filing date

2004-01-06

Publication date

2006-07-20

2004-01-06 Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC

2006-07-20 Publication of JP2006517201A publication Critical patent/JP2006517201A/ja

2006-12-21 Publication of JP2006517201A5 publication Critical patent/JP2006517201A5/ja

Status Pending legal-status Critical Current

Links

150000001408 amides Chemical class 0.000 title description 7
239000011159 matrix material Substances 0.000 title description 4
150000002148 esters Chemical class 0.000 title description 3
239000003475 metalloproteinase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 426
150000003839 salts Chemical class 0.000 claims abstract description 159
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 55
201000010099 disease Diseases 0.000 claims abstract description 49
201000008482 osteoarthritis Diseases 0.000 claims abstract description 30
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 15
206010006187 Breast cancer Diseases 0.000 claims abstract description 14
208000026310 Breast neoplasm Diseases 0.000 claims abstract description 14
125000005466 alkylenyl group Chemical group 0.000 claims description 154
229910052760 oxygen Inorganic materials 0.000 claims description 58
229910052799 carbon Inorganic materials 0.000 claims description 57
239000003814 drug Substances 0.000 claims description 48
125000001424 substituent group Chemical group 0.000 claims description 40
229910052757 nitrogen Inorganic materials 0.000 claims description 38
229910052717 sulfur Inorganic materials 0.000 claims description 32
125000004432 carbon atom Chemical group C* 0.000 claims description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
150000001721 carbon Chemical group 0.000 claims description 23
125000005842 heteroatom Chemical group 0.000 claims description 22
125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
229910052739 hydrogen Inorganic materials 0.000 claims description 17
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
125000004429 atom Chemical group 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
125000004434 sulfur atom Chemical group 0.000 claims description 13
206010019280 Heart failures Diseases 0.000 claims description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
125000000753 cycloalkyl group Chemical group 0.000 claims description 11
125000003342 alkenyl group Chemical group 0.000 claims description 10
229910052731 fluorine Inorganic materials 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 9
150000005363 heterobiaryls Chemical group 0.000 claims description 9
125000001624 naphthyl group Chemical group 0.000 claims description 9
125000001072 heteroaryl group Chemical group 0.000 claims description 8
208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
125000005843 halogen group Chemical group 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
150000001602 bicycloalkyls Chemical group 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 5
QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 claims description 4
SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 claims description 4
JNIUBAKGLCSMHL-UHFFFAOYSA-N 4-[[7-[[2-(4-methoxyphenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C=CN(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 JNIUBAKGLCSMHL-UHFFFAOYSA-N 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 claims description 4
MGMNVFVZLKLAKI-UHFFFAOYSA-N 4-[[6-[[2-(3-methoxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)NC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C=NC3=CC=2)=C1 MGMNVFVZLKLAKI-UHFFFAOYSA-N 0.000 claims description 3
FNOKXUZNEZKTID-UHFFFAOYSA-N 4-[[7-fluoro-6-[[2-(3-methoxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)NC=2C(=CC3=C(C(N(CC=4C=CC(=CC=4)C(O)=O)C=N3)=O)C=2)F)=C1 FNOKXUZNEZKTID-UHFFFAOYSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
SEVFVQQIBUFXAH-UHFFFAOYSA-N 4-[[6-[[2-(3-fluorophenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(NC(=O)CC=3C=C(F)C=CC=3)=CC=C2N=C1 SEVFVQQIBUFXAH-UHFFFAOYSA-N 0.000 claims description 2
BJIBNAAJSFJWFC-UHFFFAOYSA-N 4-[[6-[[2-(4-fluorophenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(NC(=O)CC=3C=CC(F)=CC=3)=CC=C2N=C1 BJIBNAAJSFJWFC-UHFFFAOYSA-N 0.000 claims description 2
FIGLODNTFSLAOE-UHFFFAOYSA-N 4-[[6-[[2-(4-methoxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(N=CN(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 FIGLODNTFSLAOE-UHFFFAOYSA-N 0.000 claims description 2
YRUGWXYRPLVZIZ-UHFFFAOYSA-N 4-[[7-[[2-(3-fluorophenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(NC(=O)CC=3C=C(F)C=CC=3)=CC=C2C=C1 YRUGWXYRPLVZIZ-UHFFFAOYSA-N 0.000 claims description 2
NICWGLVRVTVTBL-UHFFFAOYSA-N 4-[[7-[[2-(3-methoxyphenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)NC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C=CC3=CC=2)=C1 NICWGLVRVTVTBL-UHFFFAOYSA-N 0.000 claims description 2
JDYPXRRUKLBIFN-UHFFFAOYSA-N 4-[[7-[[2-(4-fluorophenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(NC(=O)CC=3C=CC(F)=CC=3)=CC=C2C=C1 JDYPXRRUKLBIFN-UHFFFAOYSA-N 0.000 claims description 2
WIEWWIBNEZMJBA-UHFFFAOYSA-N 4-[[7-fluoro-6-[[2-(4-hydroxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(NC(=O)CC=3C=CC(O)=CC=3)=C(F)C=C2N=C1 WIEWWIBNEZMJBA-UHFFFAOYSA-N 0.000 claims description 2
CWIDGUXFPGDYMT-UHFFFAOYSA-N 4-[[7-fluoro-6-[[2-(4-methoxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC(C(N(CC=2C=CC(=CC=2)C(O)=O)C=N2)=O)=C2C=C1F CWIDGUXFPGDYMT-UHFFFAOYSA-N 0.000 claims description 2
UAVASPSWNAENQY-UHFFFAOYSA-N 4-[[7-fluoro-6-[[2-(4-methylphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C)=CC=C1CC(=O)NC1=CC(C(N(CC=2C=CC(=CC=2)C(O)=O)C=N2)=O)=C2C=C1F UAVASPSWNAENQY-UHFFFAOYSA-N 0.000 claims description 2
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
229910052720 vanadium Inorganic materials 0.000 claims description 2
102100027995 Collagenase 3 Human genes 0.000 abstract description 114
108050005238 Collagenase 3 Proteins 0.000 abstract description 110
239000003112 inhibitor Substances 0.000 abstract description 99
102000004190 Enzymes Human genes 0.000 abstract description 81
108090000790 Enzymes Proteins 0.000 abstract description 81
206010007710 Cartilage injury Diseases 0.000 abstract description 31
230000001404 mediated effect Effects 0.000 abstract description 17
239000000126 substance Substances 0.000 abstract description 6
-1 ester compounds Chemical class 0.000 description 183
229940088598 enzyme Drugs 0.000 description 80
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 74
238000003556 assay Methods 0.000 description 62
238000000034 method Methods 0.000 description 48
102000002274 Matrix Metalloproteinases Human genes 0.000 description 44
108010000684 Matrix Metalloproteinases Proteins 0.000 description 44
239000000203 mixture Substances 0.000 description 43
238000010170 biological method Methods 0.000 description 37
239000000758 substrate Substances 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
241001465754 Metazoa Species 0.000 description 32
229940079593 drug Drugs 0.000 description 32
230000005764 inhibitory process Effects 0.000 description 31
230000003197 catalytic effect Effects 0.000 description 28
239000000243 solution Substances 0.000 description 28
230000002401 inhibitory effect Effects 0.000 description 27
239000002253 acid Substances 0.000 description 25
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
102000029816 Collagenase Human genes 0.000 description 22
108060005980 Collagenase Proteins 0.000 description 22
102000016611 Proteoglycans Human genes 0.000 description 22
108010067787 Proteoglycans Proteins 0.000 description 22
210000000845 cartilage Anatomy 0.000 description 22
229960002424 collagenase Drugs 0.000 description 22
230000000694 effects Effects 0.000 description 22
238000011282 treatment Methods 0.000 description 22
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 20
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 20
125000003118 aryl group Chemical group 0.000 description 20
238000002360 preparation method Methods 0.000 description 20
238000007792 addition Methods 0.000 description 19
238000012360 testing method Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
230000004054 inflammatory process Effects 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 16
NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 16
125000002619 bicyclic group Chemical group 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 16
125000004430 oxygen atom Chemical group O* 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000004480 active ingredient Substances 0.000 description 15
239000012131 assay buffer Substances 0.000 description 15
230000003628 erosive effect Effects 0.000 description 15
235000019439 ethyl acetate Nutrition 0.000 description 15
238000009472 formulation Methods 0.000 description 15
206010061218 Inflammation Diseases 0.000 description 14
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 14
102100030416 Stromelysin-1 Human genes 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
238000010790 dilution Methods 0.000 description 14
239000012895 dilution Substances 0.000 description 14
231100000252 nontoxic Toxicity 0.000 description 14
230000003000 nontoxic effect Effects 0.000 description 14
239000007787 solid Substances 0.000 description 14
0 CN(C=CC(N1C)=O)*1=O Chemical compound CN(C=CC(N1C)=O)*1=O 0.000 description 13
241000124008 Mammalia Species 0.000 description 13
208000002193 Pain Diseases 0.000 description 13
229920001436 collagen Polymers 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 12
108010035532 Collagen Proteins 0.000 description 12
102000008186 Collagen Human genes 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
101710108790 Stromelysin-1 Proteins 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
229940124597 therapeutic agent Drugs 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
229940124639 Selective inhibitor Drugs 0.000 description 11
102000004142 Trypsin Human genes 0.000 description 11
108090000631 Trypsin Proteins 0.000 description 11
206010003246 arthritis Diseases 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
239000011550 stock solution Substances 0.000 description 11
239000012588 trypsin Substances 0.000 description 11
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 10
125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 10
102100026802 72 kDa type IV collagenase Human genes 0.000 description 10
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000003826 tablet Substances 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
241000283690 Bos taurus Species 0.000 description 9
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
102100030417 Matrilysin Human genes 0.000 description 9
108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 9
102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 9
229960002591 hydroxyproline Drugs 0.000 description 9
239000007788 liquid Substances 0.000 description 9
125000006239 protecting group Chemical group 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
229910052725 zinc Inorganic materials 0.000 description 9
241000282412 Homo Species 0.000 description 8
102100027998 Macrophage metalloelastase Human genes 0.000 description 8
108090000855 Matrilysin Proteins 0.000 description 8
241000700159 Rattus Species 0.000 description 8
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
230000003281 allosteric effect Effects 0.000 description 8
239000002585 base Substances 0.000 description 8
230000008901 benefit Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
210000000548 hind-foot Anatomy 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000011701 zinc Substances 0.000 description 8
101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
239000007995 HEPES buffer Substances 0.000 description 7
101710187853 Macrophage metalloelastase Proteins 0.000 description 7
108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 7
102100030411 Neutrophil collagenase Human genes 0.000 description 7
101710118230 Neutrophil collagenase Proteins 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
239000002775 capsule Substances 0.000 description 7
230000006378 damage Effects 0.000 description 7
230000005284 excitation Effects 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
238000006460 hydrolysis reaction Methods 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 7
210000000629 knee joint Anatomy 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
125000002950 monocyclic group Chemical group 0.000 description 7
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
230000003349 osteoarthritic effect Effects 0.000 description 7
239000002464 receptor antagonist Substances 0.000 description 7
229940044551 receptor antagonist Drugs 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
108091006146 Channels Proteins 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
241000282326 Felis catus Species 0.000 description 6
102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
241001494479 Pecora Species 0.000 description 6
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000001188 articular cartilage Anatomy 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
125000001153 fluoro group Chemical group F* 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
230000008407 joint function Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000013598 vector Substances 0.000 description 6
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 5
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
102000013382 Gelatinases Human genes 0.000 description 5
108010026132 Gelatinases Proteins 0.000 description 5
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 5
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 5
101710176384 Peptide 1 Proteins 0.000 description 5
241000282887 Suidae Species 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000002917 arthritic effect Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
210000001612 chondrocyte Anatomy 0.000 description 5
239000003636 conditioned culture medium Substances 0.000 description 5
125000004093 cyano group Chemical group *C#N 0.000 description 5
208000037765 diseases and disorders Diseases 0.000 description 5
210000002744 extracellular matrix Anatomy 0.000 description 5
239000000796 flavoring agent Substances 0.000 description 5
210000002683 foot Anatomy 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
210000003127 knee Anatomy 0.000 description 5
125000004043 oxo group Chemical group O=* 0.000 description 5
208000028169 periodontal disease Diseases 0.000 description 5
239000007858 starting material Substances 0.000 description 5
YDKSBFMJVSHBGN-UHFFFAOYSA-N tert-butyl 4-[(6-amino-7-fluoro-4-oxoquinazolin-3-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2=CC(N)=C(F)C=C2N=C1 YDKSBFMJVSHBGN-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 4
NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
108010037464 Cyclooxygenase 1 Proteins 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
229940124761 MMP inhibitor Drugs 0.000 description 4
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 4
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 4
229960001171 acetohydroxamic acid Drugs 0.000 description 4
239000000674 adrenergic antagonist Substances 0.000 description 4
108010003059 aggrecanase Proteins 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
230000011382 collagen catabolic process Effects 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000013024 dilution buffer Substances 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
230000003902 lesion Effects 0.000 description 4
238000005567 liquid scintillation counting Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
210000002184 nasal cartilage Anatomy 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
108091007196 stromelysin Proteins 0.000 description 4
150000003463 sulfur Chemical group 0.000 description 4
239000000725 suspension Substances 0.000 description 4
YBDCTJZUOJVXKB-UHFFFAOYSA-N tert-butyl 4-(6-iodo-4-oxoquinazolin-3-yl)benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1N1C(=O)C2=CC(I)=CC=C2N=C1 YBDCTJZUOJVXKB-UHFFFAOYSA-N 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 3
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
102000000503 Collagen Type II Human genes 0.000 description 3
108010041390 Collagen Type II Proteins 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241000283086 Equidae Species 0.000 description 3
201000005569 Gout Diseases 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
206010023230 Joint stiffness Diseases 0.000 description 3
208000003456 Juvenile Arthritis Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
101150014058 MMP1 gene Proteins 0.000 description 3
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
210000003423 ankle Anatomy 0.000 description 3
230000002456 anti-arthritic effect Effects 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
208000007474 aortic aneurysm Diseases 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
108700004333 collagenase 1 Proteins 0.000 description 3
239000003086 colorant Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
229940111134 coxibs Drugs 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
229910052737 gold Inorganic materials 0.000 description 3
239000010931 gold Substances 0.000 description 3
239000008240 homogeneous mixture Substances 0.000 description 3
229920002674 hyaluronan Polymers 0.000 description 3
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
229960004171 hydroxychloroquine Drugs 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
238000005462 in vivo assay Methods 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 3
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
244000144972 livestock Species 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
208000002780 macular degeneration Diseases 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 3
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
229940055729 papain Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
229960001639 penicillamine Drugs 0.000 description 3
239000006187 pill Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
238000011552 rat model Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
DXCFMNFSJQLHLT-UHFFFAOYSA-N tert-butyl 4-[(7-amino-1-oxoisoquinolin-2-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2=CC(N)=CC=C2C=C1 DXCFMNFSJQLHLT-UHFFFAOYSA-N 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
YEAUYVGUXSZCFI-UHFFFAOYSA-N 2-(3-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1 YEAUYVGUXSZCFI-UHFFFAOYSA-N 0.000 description 2
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 2
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
241000282465 Canis Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
208000028006 Corneal injury Diseases 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010013935 Dysmenorrhoea Diseases 0.000 description 2
102000009079 Epoprostenol Receptors Human genes 0.000 description 2
108010073099 Epoprostenol Receptors Proteins 0.000 description 2
241000283087 Equus Species 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
241000282324 Felis Species 0.000 description 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 2
101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
108090000560 Matrix metalloproteinase-15 Proteins 0.000 description 2
108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 2
102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 2
102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 2
102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 2
108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 2
102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 2
102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
102000056189 Neutrophil collagenases Human genes 0.000 description 2
108030001564 Neutrophil collagenases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000008866 Prostaglandin E receptors Human genes 0.000 description 2
108010088540 Prostaglandin E receptors Proteins 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
102100028848 Stromelysin-2 Human genes 0.000 description 2
102100028847 Stromelysin-3 Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010064996 Ulcerative keratitis Diseases 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
229940122803 Vinca alkaloid Drugs 0.000 description 2
101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
229960003459 allopurinol Drugs 0.000 description 2
230000008850 allosteric inhibition Effects 0.000 description 2
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000002255 antigout agent Substances 0.000 description 2
229960002708 antigout preparations Drugs 0.000 description 2
239000003080 antimitotic agent Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
229960002529 benzbromarone Drugs 0.000 description 2
102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
238000012742 biochemical analysis Methods 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000002327 cardiovascular agent Substances 0.000 description 2
229940125692 cardiovascular agent Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008355 cartilage degradation Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
239000002442 collagenase inhibitor Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
201000007717 corneal ulcer Diseases 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
229960004945 etoricoxib Drugs 0.000 description 2
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
230000036732 histological change Effects 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
230000037231 joint health Effects 0.000 description 2
208000018937 joint inflammation Diseases 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
238000002372 labelling Methods 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
108090000440 matrix metalloproteinase 25 Proteins 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
239000006225 natural substrate Substances 0.000 description 2
NOUWNNABOUGTDQ-UHFFFAOYSA-N octane Chemical compound CCCCCCC[CH2+] NOUWNNABOUGTDQ-UHFFFAOYSA-N 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000013641 positive control Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
229960003081 probenecid Drugs 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
239000002089 prostaglandin antagonist Substances 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
229960003329 sulfinpyrazone Drugs 0.000 description 2
MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
201000004595 synovitis Diseases 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
YBYRRRIMUVFNOP-UHFFFAOYSA-N tert-butyl 4-[(7-fluoro-6-nitro-4-oxoquinazolin-3-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1CN1C(=O)C2=CC([N+]([O-])=O)=C(F)C=C2N=C1 YBYRRRIMUVFNOP-UHFFFAOYSA-N 0.000 description 2
LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
210000002303 tibia Anatomy 0.000 description 2
CNHDIAIOKMXOLK-UHFFFAOYSA-N toluquinol Chemical compound CC1=CC(O)=CC=C1O CNHDIAIOKMXOLK-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000005747 tumor angiogenesis Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
RVAKJCIYNQKYOG-UHFFFAOYSA-N 1-benzyl-1-(dicyclohexylmethyl)-2,2-diethylhydrazine Chemical compound C1CCCCC1C(C1CCCCC1)N(N(CC)CC)CC1=CC=CC=C1 RVAKJCIYNQKYOG-UHFFFAOYSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
GXXXUZIRGXYDFP-UHFFFAOYSA-N 2-(4-methylphenyl)acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1 GXXXUZIRGXYDFP-UHFFFAOYSA-N 0.000 description 1
XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
KAVRHMCFFIUYLI-UHFFFAOYSA-N 4-[(6-amino-7-fluoro-4-oxoquinazolin-3-yl)methyl]benzoic acid Chemical compound NC=1C=C2C(N(C=NC2=CC1F)CC1=CC=C(C(=O)O)C=C1)=O KAVRHMCFFIUYLI-UHFFFAOYSA-N 0.000 description 1
AMEKIYOUZARTDP-UHFFFAOYSA-N 4-[(7-bromo-1-oxoisoquinolin-2-yl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2C=C1 AMEKIYOUZARTDP-UHFFFAOYSA-N 0.000 description 1
TVZDWYYXHAIMCR-UHFFFAOYSA-N 4-[[2-[[1-[6-amino-2-[[1-[5-carbamimidamido-2-[[2-(7-methoxy-2-oxochromen-4-yl)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-5-[[1-[[1-[[1-[[1-amino-6-(2,4-dinitroanilino)-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCCC(NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C1CCCN1C(=O)C(CCCNC(N)=N)NC(=O)CC1=CC(=O)Oc2cc(OC)ccc12)C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCNc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O TVZDWYYXHAIMCR-UHFFFAOYSA-N 0.000 description 1
DYFRQWFYRDCCOU-UHFFFAOYSA-N 4-[[6-[2-(3-fluorophenyl)acetyl]oxy-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(OC(=O)CC=3C=C(F)C=CC=3)=CC=C2N=C1 DYFRQWFYRDCCOU-UHFFFAOYSA-N 0.000 description 1
JCOHPYCQRLLILA-UHFFFAOYSA-N 4-[[6-[2-(3-methoxyphenyl)acetyl]oxy-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)OC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C(=O)N(C)C3=CC=2)=C1 JCOHPYCQRLLILA-UHFFFAOYSA-N 0.000 description 1
PZXTXIAYXSSFGD-UHFFFAOYSA-N 4-[[6-[2-(3-methoxyphenyl)acetyl]oxy-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)OC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C=NC3=CC=2)=C1 PZXTXIAYXSSFGD-UHFFFAOYSA-N 0.000 description 1
VEJKCEIXWOOXBW-UHFFFAOYSA-N 4-[[6-[2-(4-fluorophenyl)acetyl]oxy-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=C2C(=O)N(CC=3C=CC(=CC=3)C(O)=O)C(=O)N(C)C2=CC=C1OC(=O)CC1=CC=C(F)C=C1 VEJKCEIXWOOXBW-UHFFFAOYSA-N 0.000 description 1
FUECTYICWMMNBK-UHFFFAOYSA-N 4-[[6-[2-(4-fluorophenyl)acetyl]oxy-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(OC(=O)CC=3C=CC(F)=CC=3)=CC=C2N=C1 FUECTYICWMMNBK-UHFFFAOYSA-N 0.000 description 1
AQJNLPWPMHIYRL-UHFFFAOYSA-N 4-[[6-[2-(4-methoxyphenyl)acetyl]oxy-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)OC1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 AQJNLPWPMHIYRL-UHFFFAOYSA-N 0.000 description 1
UWWAUEVJDALVAW-UHFFFAOYSA-N 4-[[6-[2-(4-methoxyphenyl)acetyl]oxy-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)OC1=CC=C(N=CN(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 UWWAUEVJDALVAW-UHFFFAOYSA-N 0.000 description 1
RYBYWHRIWZXGKS-UHFFFAOYSA-N 4-[[6-[[2-(3-methoxyphenyl)acetyl]amino]-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)NC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C(=O)N(C)C3=CC=2)=C1 RYBYWHRIWZXGKS-UHFFFAOYSA-N 0.000 description 1
VFAGDNFVKHZTJI-UHFFFAOYSA-N 4-[[6-[[2-(4-fluorophenyl)acetyl]amino]-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=C2C(=O)N(CC=3C=CC(=CC=3)C(O)=O)C(=O)N(C)C2=CC=C1NC(=O)CC1=CC=C(F)C=C1 VFAGDNFVKHZTJI-UHFFFAOYSA-N 0.000 description 1
BRAKYGMAMLVEPS-UHFFFAOYSA-N 4-[[6-[[2-(4-methoxyphenyl)acetyl]amino]-1-methyl-2,4-dioxoquinazolin-3-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(N(C)C(=O)N(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 BRAKYGMAMLVEPS-UHFFFAOYSA-N 0.000 description 1
QTVLYBZPRCHLBK-UHFFFAOYSA-N 4-[[7-[2-(3-fluorophenyl)acetyl]oxy-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(OC(=O)CC=3C=C(F)C=CC=3)=CC=C2C=C1 QTVLYBZPRCHLBK-UHFFFAOYSA-N 0.000 description 1
AWJFATBYQBCWLI-UHFFFAOYSA-N 4-[[7-[2-(3-methoxyphenyl)acetyl]oxy-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)OC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(O)=O)C=CC3=CC=2)=C1 AWJFATBYQBCWLI-UHFFFAOYSA-N 0.000 description 1
DMFIOOQMPCGXDW-UHFFFAOYSA-N 4-[[7-[2-(4-fluorophenyl)acetyl]oxy-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(OC(=O)CC=3C=CC(F)=CC=3)=CC=C2C=C1 DMFIOOQMPCGXDW-UHFFFAOYSA-N 0.000 description 1
WTHBRKKFABPEAH-UHFFFAOYSA-N 4-[[7-[2-(4-methoxyphenyl)acetyl]oxy-1-oxoisoquinolin-2-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)OC1=CC=C(C=CN(CC=2C=CC(=CC=2)C(O)=O)C2=O)C2=C1 WTHBRKKFABPEAH-UHFFFAOYSA-N 0.000 description 1
MRJRFEMIPOBQPR-UHFFFAOYSA-N 4-[[7-fluoro-6-[2-(3-methoxyphenyl)acetyl]oxy-4-oxoquinazolin-3-yl]methyl]benzoic acid Chemical compound COC1=CC=CC(CC(=O)OC=2C(=CC3=C(C(N(CC=4C=CC(=CC=4)C(O)=O)C=N3)=O)C=2)F)=C1 MRJRFEMIPOBQPR-UHFFFAOYSA-N 0.000 description 1
SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical class C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102000017304 72kDa type IV collagenases Human genes 0.000 description 1
108050005269 72kDa type IV collagenases Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102100036601 Aggrecan core protein Human genes 0.000 description 1
108010067219 Aggrecans Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229940124810 Alzheimer's drug Drugs 0.000 description 1
102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000283725 Bos Species 0.000 description 1
101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
YKYHLGIJMQCJTR-UHFFFAOYSA-N C=CSc1ccc(CN(C2=O)S)c2c1 Chemical compound C=CSc1ccc(CN(C2=O)S)c2c1 YKYHLGIJMQCJTR-UHFFFAOYSA-N 0.000 description 1
AXTDTRDEHRVHTG-UHFFFAOYSA-N CC(C(N1C)=O)=CNS1(=O)=O Chemical compound CC(C(N1C)=O)=CNS1(=O)=O AXTDTRDEHRVHTG-UHFFFAOYSA-N 0.000 description 1
HMPSFGAPPOPWHP-UHFFFAOYSA-N CC(C(Nc(c1c2)ccc2S)=O)=C1O Chemical compound CC(C(Nc(c1c2)ccc2S)=O)=C1O HMPSFGAPPOPWHP-UHFFFAOYSA-N 0.000 description 1
DVTLDZMNARPDNW-UHFFFAOYSA-N CC(C(c(cc(C)cc1)c1O1)=O)C1=O Chemical compound CC(C(c(cc(C)cc1)c1O1)=O)C1=O DVTLDZMNARPDNW-UHFFFAOYSA-N 0.000 description 1
BFUDQAWXYBVTAV-UHFFFAOYSA-N CC(C(c(cc(C)nn1)c1O1)=O)C1=O Chemical compound CC(C(c(cc(C)nn1)c1O1)=O)C1=O BFUDQAWXYBVTAV-UHFFFAOYSA-N 0.000 description 1
JZYMRGJPJNQWNR-UHFFFAOYSA-N CC(C(c(nc(C)cc1)c1O1)=O)C1=O Chemical compound CC(C(c(nc(C)cc1)c1O1)=O)C1=O JZYMRGJPJNQWNR-UHFFFAOYSA-N 0.000 description 1
GMBMLTMYTXNIST-UHFFFAOYSA-N CC(C(c(nc(C)cn1)c1O1)=O)C1=O Chemical compound CC(C(c(nc(C)cn1)c1O1)=O)C1=O GMBMLTMYTXNIST-UHFFFAOYSA-N 0.000 description 1
AGFGQWSIVAXQFK-UHFFFAOYSA-N CC(C=CC1=C2)=CC1=CN(C)C2=O Chemical compound CC(C=CC1=C2)=CC1=CN(C)C2=O AGFGQWSIVAXQFK-UHFFFAOYSA-N 0.000 description 1
AKZNEOBTLOYDLV-UHFFFAOYSA-N CN(C(C=C(C=C1)N2C=C1S)=O)C2=O Chemical compound CN(C(C=C(C=C1)N2C=C1S)=O)C2=O AKZNEOBTLOYDLV-UHFFFAOYSA-N 0.000 description 1
OPBOCYUAFCCQNF-UHFFFAOYSA-N CN(C=CC(N1C)=O)S1(O)=O Chemical compound CN(C=CC(N1C)=O)S1(O)=O OPBOCYUAFCCQNF-UHFFFAOYSA-N 0.000 description 1
MSMWTKAJZRFGQT-UHFFFAOYSA-N CN(c1ncc[n]1-c(c1c2)ccc2S)C1=O Chemical compound CN(c1ncc[n]1-c(c1c2)ccc2S)C1=O MSMWTKAJZRFGQT-UHFFFAOYSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
HLCOTTZFIBFBKV-NUHJPDEHSA-N Cc(cc1)cc(C(N2C)=O)c1N1C2=NC(C2)[C@H]2C=C1 Chemical compound Cc(cc1)cc(C(N2C)=O)c1N1C2=NC(C2)[C@H]2C=C1 HLCOTTZFIBFBKV-NUHJPDEHSA-N 0.000 description 1
DGRSYONZYAQTRS-UHFFFAOYSA-N Cc(cc1)cc(cc2C)c1nc2O Chemical compound Cc(cc1)cc(cc2C)c1nc2O DGRSYONZYAQTRS-UHFFFAOYSA-N 0.000 description 1
CLOGRMYLWKJZDL-UHFFFAOYSA-N Cc(cc1)cc2c1N=CN(C)S2(=O)=O Chemical compound Cc(cc1)cc2c1N=CN(C)S2(=O)=O CLOGRMYLWKJZDL-UHFFFAOYSA-N 0.000 description 1
LRQYSMQNJLZKPS-UHFFFAOYSA-N Cc(cc1)cc2c1ccc(C)c2 Chemical compound Cc(cc1)cc2c1ccc(C)c2 LRQYSMQNJLZKPS-UHFFFAOYSA-N 0.000 description 1
GSSCKRKJWCRYLR-UHFFFAOYSA-N Cc(cc1)cc2c1ccc(C)c2O Chemical compound Cc(cc1)cc2c1ccc(C)c2O GSSCKRKJWCRYLR-UHFFFAOYSA-N 0.000 description 1
BXZIXFZODFTHOR-UHFFFAOYSA-N Cc(cc12)ccc1N=CN(C)C2=O Chemical compound Cc(cc12)ccc1N=CN(C)C2=O BXZIXFZODFTHOR-UHFFFAOYSA-N 0.000 description 1
WCWLCNRHXYGEAD-UHFFFAOYSA-N Cc(cc1C(N2C)=O)ccc1OS2(=O)=O Chemical compound Cc(cc1C(N2C)=O)ccc1OS2(=O)=O WCWLCNRHXYGEAD-UHFFFAOYSA-N 0.000 description 1
HMVGODXCRPDLGH-UHFFFAOYSA-N Cc(cc1C(N2C)=O)cnc1-[n]1c2ncc1 Chemical compound Cc(cc1C(N2C)=O)cnc1-[n]1c2ncc1 HMVGODXCRPDLGH-UHFFFAOYSA-N 0.000 description 1
KDHWUJCNSJGWJD-UHFFFAOYSA-N Cc(cc1S(N2C)(=O)=O)ccc1NC2=O Chemical compound Cc(cc1S(N2C)(=O)=O)ccc1NC2=O KDHWUJCNSJGWJD-UHFFFAOYSA-N 0.000 description 1
PXZWJPFLBASWCR-UHFFFAOYSA-N Cc(nc1)cc(C(N2C)=O)c1-[n]1c2ncc1 Chemical compound Cc(nc1)cc(C(N2C)=O)c1-[n]1c2ncc1 PXZWJPFLBASWCR-UHFFFAOYSA-N 0.000 description 1
GBOZYOUZKCYGJK-UHFFFAOYSA-N Cc(nc1C(N2C)=O)ccc1-[n]1c2ncc1 Chemical compound Cc(nc1C(N2C)=O)ccc1-[n]1c2ncc1 GBOZYOUZKCYGJK-UHFFFAOYSA-N 0.000 description 1
PPMIHGAKMOUVRH-UHFFFAOYSA-N Cc1ccc(C=CN(C)S2(=O)=O)c2c1 Chemical compound Cc1ccc(C=CN(C)S2(=O)=O)c2c1 PPMIHGAKMOUVRH-UHFFFAOYSA-N 0.000 description 1
DBJJDHJURGQEPE-UHFFFAOYSA-N Cc1ccc(CC(N(C)S2(=O)=O)=O)c2c1 Chemical compound Cc1ccc(CC(N(C)S2(=O)=O)=O)c2c1 DBJJDHJURGQEPE-UHFFFAOYSA-N 0.000 description 1
MSUDAPCGURFTJI-UHFFFAOYSA-N Cc1ccc(CS(N(C)C2=O)(=O)=O)c2c1 Chemical compound Cc1ccc(CS(N(C)C2=O)(=O)=O)c2c1 MSUDAPCGURFTJI-UHFFFAOYSA-N 0.000 description 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
229940122097 Collagenase inhibitor Drugs 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000033131 Congenital factor II deficiency Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010011044 Corneal scar Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
238000006969 Curtius rearrangement reaction Methods 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010011985 Decubitus ulcer Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102100035094 Enamelin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229940124602 FDA-approved drug Drugs 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
206010061172 Gastrointestinal injury Diseases 0.000 description 1
241000224466 Giardia Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000007646 Hypoprothrombinemias Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
206010024453 Ligament sprain Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
102000055008 Matrilin Proteins Human genes 0.000 description 1
108010072582 Matrilin Proteins Proteins 0.000 description 1
108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
102000004043 Matrix metalloproteinase-15 Human genes 0.000 description 1
102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
102000004044 Matrix metalloproteinase-16 Human genes 0.000 description 1
102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
102000004054 Matrix metalloproteinase-17 Human genes 0.000 description 1
102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
102100029693 Matrix metalloproteinase-20 Human genes 0.000 description 1
108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
101710082411 Matrix metalloproteinase-21 Proteins 0.000 description 1
108050006284 Matrix metalloproteinase-23 Proteins 0.000 description 1
102100024132 Matrix metalloproteinase-27 Human genes 0.000 description 1
108050005201 Matrix metalloproteinase-27 Proteins 0.000 description 1
102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010050031 Muscle strain Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
241000283898 Ovis Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
241000282579 Pan Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
229920001774 Perfluoroether Chemical group 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000034712 Rickettsia Infections Diseases 0.000 description 1
206010061495 Rickettsiosis Diseases 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
108050005271 Stromelysin-3 Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
206010044302 Tracheitis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
229940125528 allosteric inhibitor Drugs 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
210000001264 anterior cruciate ligament Anatomy 0.000 description 1
125000005427 anthranyl group Chemical group 0.000 description 1
230000007131 anti Alzheimer effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
229960005207 auranofin Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000005130 benzoxazines Chemical group 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229940110331 bextra Drugs 0.000 description 1
125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000003245 coal Substances 0.000 description 1
230000037410 cognitive enhancement Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000004145 cyclopenten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000007784 diverticulitis Diseases 0.000 description 1
229960003530 donepezil Drugs 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
210000001162 elastic cartilage Anatomy 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
239000002792 enkephalinase inhibitor Substances 0.000 description 1
238000005837 enolization reaction Methods 0.000 description 1
210000002409 epiglottis Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000000968 fibrocartilage Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229950007979 flufenisal Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960002870 gabapentin Drugs 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
229940005494 general anesthetics Drugs 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000009033 hematopoietic malignancy Effects 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
239000000938 histamine H1 antagonist Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
229940048921 humira Drugs 0.000 description 1
229940018991 hyalgan Drugs 0.000 description 1
210000004276 hyalin Anatomy 0.000 description 1
210000003035 hyaline cartilage Anatomy 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
229950002252 isoxicam Drugs 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000003367 kinetic assay Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
229960002367 lasofoxifene Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
229940096405 magnesium cation Drugs 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229960001952 metrifonate Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229940101972 mirapex Drugs 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
238000011228 multimodal treatment Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000019261 negative regulation of glycolysis Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
239000012740 non-selective inhibitor Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229960004662 parecoxib Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
125000005010 perfluoroalkyl group Chemical group 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
102000030769 platelet activating factor receptor Human genes 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
229960001233 pregabalin Drugs 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000004672 propanoic acids Chemical class 0.000 description 1
229960002934 propentofylline Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
150000005599 propionic acid derivatives Chemical class 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000007183 prothrombin deficiency Diseases 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
FLTFWLUOHKERMJ-UHFFFAOYSA-N pyrano[3,4-b]pyrrole Chemical compound C1=COC=C2N=CC=C21 FLTFWLUOHKERMJ-UHFFFAOYSA-N 0.000 description 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006894 reductive elimination reaction Methods 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
229940113775 requip Drugs 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229950005175 sudoxicam Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
229940036220 synvisc Drugs 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-O tacrine(1+) Chemical compound C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-O 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 1
URRRJFZPQRIPQP-UHFFFAOYSA-N tert-butyl 4-[[6-[[2-(3-methoxyphenyl)acetyl]amino]-4-oxoquinazolin-3-yl]methyl]benzoate Chemical compound COC1=CC=CC(CC(=O)NC=2C=C3C(=O)N(CC=4C=CC(=CC=4)C(=O)OC(C)(C)C)C=NC3=CC=2)=C1 URRRJFZPQRIPQP-UHFFFAOYSA-N 0.000 description 1
UEGYVMOIGIHHCQ-UHFFFAOYSA-N tert-butyl 4-[[7-[[2-(4-methoxyphenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]methyl]benzoate Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C=CN(CC=2C=CC(=CC=2)C(=O)OC(C)(C)C)C2=O)C2=C1 UEGYVMOIGIHHCQ-UHFFFAOYSA-N 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
125000005503 thioxanyl group Chemical group 0.000 description 1
239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
125000005455 trithianyl group Chemical group 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
108010022248 tuftelin Proteins 0.000 description 1
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000273 veterinary drug Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229940087652 vioxx Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000004383 yellowing Methods 0.000 description 1
229940006486 zinc cation Drugs 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1